Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3353627
Max Phase: Preclinical
Molecular Formula: C29H52F9N7O6
Molecular Weight: 423.69
Molecule Type: Small molecule
Associated Items:
ID: ALA3353627
Max Phase: Preclinical
Molecular Formula: C29H52F9N7O6
Molecular Weight: 423.69
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(CCCCCCCCNCCCCCCCCNC(=N)N)C(=N)NCC1CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C23H49N7.3C2HF3O2/c1-30(23(26)29-20-21-14-15-21)19-13-9-5-4-7-11-17-27-16-10-6-2-3-8-12-18-28-22(24)25;3*3-2(4,5)1(6)7/h21,27H,2-20H2,1H3,(H2,26,29)(H4,24,25,28);3*(H,6,7)
Standard InChI Key: UULGETMBLKAXBJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 423.69 | Molecular Weight (Monoisotopic): 423.4049 | AlogP: 3.61 | #Rotatable Bonds: 20 |
Polar Surface Area: 113.05 | Molecular Species: BASE | HBA: 3 | HBD: 6 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 12.86 | CX LogP: 3.58 | CX LogD: -4.22 |
Aromatic Rings: 0 | Heavy Atoms: 30 | QED Weighted: 0.10 | Np Likeness Score: -0.16 |
1. Maccari G, Sanfilippo S, De Luca F, Deodato D, Casian A, Dasso Lang MC, Zamperini C, Dreassi E, Rossolini GM, Docquier JD, Botta M.. (2014) Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity., 24 (23): [PMID:25455183] [10.1016/j.bmcl.2014.09.081] |
Source(1):